Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Controlled Study of Metronomic Capecitabine Combined With Aromatase Inhibitor Versus Aromatase Inhibitor Alone for First Line Treatment in Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer

NCT02767661 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT02767661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02767661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Controlled Study of Metronomic Capecitabine Combined With Aromatase Inhibitor Versus Aromatase Inhibitor Alone for First Line Treatment in Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Completed
Start date
July 19, 2017
Completion date
August 25, 2023
Enrollment
263 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer